Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in ROIV — Roivant Sciences Ltd.

CIK 1423053 MIAMI, FL
Back to ROIV Full portfolio

Position in ROIV

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$197,343,876
+$127,650,732 QoQ
Shares Held
5,576,261
+121.6% QoQ
Ownership
0.772%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#22
of 489 holders
Holding Since
Jun 2022
17 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ROIV Over Time

Shares Held

Position Value (USD)

Derivatives in ROIV

reported options exposure · as of Jun 30, 2026
CallValue
$4,823,657
CallShares
136,300
PutValue
$3,560,234
PutShares
100,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,678,386 across 436 Biotechnology names. ROIV ranks #8 (3.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
This page 		5,576,261 $197,343,876

All Filings in ROIV

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,823,657 136,300
2026-06-30 $197,343,876 5,576,261
2026-06-30 $3,560,234 100,600
2026-03-31 $69,693,144 2,515,998
2026-03-31 $2,772,770 100,100
2026-03-31 $2,966,670 107,100
2025-12-31 $49,606,221 2,286,001
2025-12-31 $7,872,760 362,800
2025-12-31 $6,898,430 317,900
2025-09-30 $14,648,911 968,203
2025-09-30 $3,915,644 258,800
2025-09-30 $3,823,351 252,700
2025-06-30 $1,563,149 138,700
2025-06-30 $2,154,824 191,200
2025-06-30 $5,546,327 492,132
2025-03-31 $2,758,606 273,400
2025-03-31 $983,775 97,500
2025-03-31 $13,635,030 1,351,341
2024-12-31 $21,350,534 1,804,779
2024-12-31 $457,821 38,700
2024-12-31 $2,946,853 249,100
2024-09-30 $597,772 51,800
2024-09-30 $3,427,380 297,000
2024-09-30 $68,411,231 5,928,183
2024-06-30 $733,558 69,400
2024-06-30 $20,337,071 1,924,037
2024-06-30 $2,409,960 228,000
2024-03-31 $2,726,698 258,700
2024-03-31 $1,024,488 97,200
2024-03-31 $33,091,162 3,139,579
2023-12-31 $39,099,523 3,481,703
2023-12-31 $2,451,509 218,300
2023-12-31 $532,302 47,400
2023-09-30 $1,474,050 126,203
2023-09-30 $1,462,336 125,200
2023-09-30 $344,560 29,500
2023-06-30 $510,048 50,600
2023-06-30 $253,803 25,179
2023-06-30 $228,816 22,700
2023-03-31 $214,020 29,000
2023-03-31 $278,964 37,800
2023-03-31 $10,360,338 1,403,840
2022-12-31 $6,903,127 863,971
2022-12-31 $585,667 73,300
2022-12-31 $146,217 18,300
2022-09-30 $4,617,560 1,434,025
2022-09-30 $62,790 19,500
2022-09-30 $139,104 43,200
2022-06-30 $762,509 187,349
2022-06-30 $92,389 22,700

Report a Problem

Category
Description
Email (optional, for follow-up)